⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7375648 | 0.90 | HRH3 (0.41) | — | |
| SCHEMBL12717823 | 0.80 | — | — | |
| SCHEMBL1430963 | 0.80 | — | — | |
| SCHEMBL6774992 | 0.80 | — | — | |
| SCHEMBL18820447 | 0.79 | MAPK1 (0.37) | — | |
| SCHEMBL9937807 | 0.79 | MAPK1 (0.44) | — | |
| SCHEMBL2349160 | 0.77 | SIGMAR1 (0.42) | — | |
| SCHEMBL1564250 | 0.77 | SIGMAR1 (0.55) | — | |
| SCHEMBL9640541 | 0.77 | MAPK1 (0.43) | — | |
| SCHEMBL296049 | 0.77 | SIGMAR1 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317706-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-26 | — | — | US | disclosed |
| WO-2023242597-A1 | BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023242598-A1 | BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2023-12-21 | — | — | WO | disclosed |
| US-20230373952-A1 | LACTAM COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC | 2023-11-23 | — | — | US | disclosed |
| WO-2023069720-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20220135544-A1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2022-05-05 | — | — | US | disclosed |
| EP-3010501-B1 | ESTROGEN RECEPTOR MODULATOR AND USES THEREOF | SERAGON PHARMACEUTICALS INC (US) | 2021-11-03 | — | — | EP | disclosed |
| EP-3010501-B1 | ESTROGEN RECEPTOR MODULATOR AND USES THEREOF | SERAGON PHARMACEUTICALS INC (US) | 2021-11-03 | — | — | EP | disclosed |
| EP-3888657-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | Incyte Holdings Corporation (US) | 2021-10-06 | — | — | EP | disclosed |
| US-20210253571-A1 | AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR | WUXI LIFE FOUNTAIN BIOTECH CO., LTD (CN) | 2021-08-19 | — | — | US | disclosed |
| WO-2014205136-A1 | AZETIDINE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS, INC. (US) | 2014-12-24 | — | — | WO | disclosed |
| US-8895601-B2 | Pyrazolyl quinoxaline kinase inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2014-11-25 | — | — | US | disclosed |
| US-8895601-B2 | Pyrazolyl quinoxaline kinase inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2014-11-25 | — | — | US | disclosed |
| US-20130267525-A1 | SUBSTITUTED BENZOPYRAZIN DERIVATIVES AS FGFR KINASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES | ASTEX THERAPEUTICS LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20130267525-A1 | SUBSTITUTED BENZOPYRAZIN DERIVATIVES AS FGFR KINASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES | ASTEX THERAPEUTICS LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20130261101-A1 | BICYCLIC AZAHETEROCYCLOBENZYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2013-10-03 | — | — | US | disclosed |
| US-20130072457-A1 | PYRAZOLYL QUINAZOLINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2013-03-21 | — | — | US | disclosed |
| US-20130072457-A1 | PYRAZOLYL QUINAZOLINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2013-03-21 | — | — | US | disclosed |
| US-20130059835-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2013-03-07 | — | — | US | disclosed |
| WO-2011135376-A1 | PYRAZOLYL QUINAZOLINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-11-03 | — | — | WO | disclosed |